BCL2 and neoplasm: Additionally, while both apoptosis induction and antiangiogenesis likely contribute to dinaciclib's anti-tumor effect, the in vivo apoptosis response a priori will likely be enhanced through combination with drugs that downregulate or directly inhibit other BCL2-family members and thus may provide clinical benefit.